Daniel Patrick O'Day, Chairman and CEO of Gilead Sciences, Inc., filed a Form 4 on November 6, 2026, disclosing the exercise of non-qualified stock options and sale of common stock on November 4 and November 5, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercises: O'Day exercised 102,619 non-qualified stock options on November 4, 2026, and an additional 9,810 on November 5, 2026, at an exercise price of $72.34 per share.
  • Shares sold: 102,619 shares were sold on November 4, 2026, at a weighted average price of $175.1627, and 9,810 shares were sold on November 5, 2026, at $175.17 per share.
  • Remaining beneficial ownership: Following both transactions, O'Day directly owned 551,683 shares of common stock.
  • Remaining options: After the exercises, O'Day held 128,310 non-qualified stock options with an expiration date of March 10, 2030.
  • 10b5-1 plan: According to the filing, all transactions were made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.
  • Signing authority: The form was signed by Amy Kim by Power of Attorney for Daniel O'Day.

O'Day's November 2026 Option Exercises and Share Sales at Gilead Sciences

According to the Form 4 filed with the SEC on November 6, 2026, Daniel Patrick O'Day, who serves as Chairman and CEO of Gilead Sciences, Inc. (NASDAQ:GILD), carried out a series of transactions on November 4 and November 5, 2026. On November 4, O'Day exercised 102,619 non-qualified stock options at an exercise price of $72.34 per share, bringing his directly held common stock position to 654,302 shares. He then sold those 102,619 shares at a weighted average price of $175.1627, with individual sale prices ranging from $175.05 to $175.35, reducing his direct holdings to 551,683 shares.

On November 5, 2026, O'Day exercised an additional 9,810 non-qualified stock options at the same exercise price of $72.34, temporarily raising his holdings to 561,493 shares before selling those 9,810 shares at $175.17 per share, leaving his direct beneficial ownership again at 551,683 shares. The filing notes that the options exercised carry a four-year vesting schedule, with 25% vesting on the first anniversary of the grant date and the remaining balance vesting at 6.25% quarterly thereafter until fully vested.

The filing states that all transactions reported were made pursuant to a Rule 10b5-1 trading plan that O'Day adopted on February 25, 2026. Following the two days of activity, O'Day retained 128,310 non-qualified stock options, all with an expiration date of March 10, 2030, held directly.

What Was Disclosed

The filing disclosed that Gilead Sciences Chairman and CEO Daniel O'Day exercised a total of 112,429 non-qualified stock options and sold an equal number of common shares over two days under a pre-established 10b5-1 trading plan, with direct beneficial ownership of 551,683 shares remaining afterward.